Investor Relations

Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells.  Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs.  These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers.  Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging.  The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload.  CLR 131 is currently being evaluated under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma.  In addition, the company has initiated a Phase II clinical study to assess efficacy in a range of B-cell malignancies.   The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts.  For more information please visit www.cellectar.com.

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Cellectar Biosciences's financial performance into perspective.

Press Releases

Dec 14, 2017
Dec 6, 2017
Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131
Multiple myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit

Events & Presentations

Dec 5, 2017 at 11:30 AM ET
Nov 10, 2017 at 8:00 AM ET